| http://www.w3.org/ns/prov#value | - At a conference on Wednesday, Idenix President and CEO Ronald Renaud said the company is quite pleased with the safety profile that we have seen to-date for IDX184.Shares of Achillion Pharmaceuticals Inc., a company that is developing a competing hepatitis C therapy, rose 24 cents, or 4.1 percent, to $6.14.Hepatitis C is a virus that can lead to life-threatening liver damage and is the main cause
|
